Human adipose-derived stem cells: Isolation, characterization and current application in regeneration medicine  by Cheng, Kuang-Hung et al.
Genomic Medicine, Biomarkers, and Health Sciences (2011) 3, 53e62Available online at www.sciencedirect.com
journal homepage: www.e-gmbhs.comREVIEW ARTICLE
Human adipose-derived stem cells: Isolation,
characterization and current application
in regeneration medicineKuang-Hung Cheng a,*, Tzu-Lei Kuo a, Kung-Kai Kuo b, Chang-Chun Hsiao ca Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan, ROC
bDivision of Hepatobiliary Pancreatic Surgery, Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial
Hospital, Kaohsiung, Taiwan, ROC
c Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Kaohsiung, Taiwan, ROC
Received 10 January 2011; received in revised form 16 March 2011; accepted 10 May 2011
Available online 14 October 2011KEYWORDS
adipose-derived stem
cells;
adult stem cells;
differentiation;
tissue regeneration* Corresponding author. Institute
National Sun Yat-Sen University, 70
80424, Taiwan.
E-mail address: khcheng@faculty.n
2211-4254/$36 Copyright ª 2011, Taiw
doi:10.1016/j.gmbhs.2011.08.003Abstract Stem cell techniques and tissue engineering are the foundation of the emerging
field of regenerative medicine, which requires a stable source of stem or progenitor cells.
Adipose tissue has been proven to serve as an alternative, rich source of adult stem cells with
multipotent ability. There has been increased interest in adipose-derived stem cells (ADSCs)
for tissue engineering applications. Here, we review the current techniques for isolating, culti-
vating, and differentiating ADSCs, and describe them in detail. The results from many studies
that we summarize in this review indicate that ADSCs and their secretory factors show great
promise for use in stem cell therapy.
Copyright ª 2011, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Stem cells are defined as a group of undifferentiated cells
that own unlimited or prolonged self-renewal ability andof Biomedical Sciences,
Lien-hai Road, Kaohsiung
sysu.edu.tw (K.-H. Cheng).
an Genomic Medicine and Biomaalso have the capability to be induced into various mature
somatic cell types. The individual unit of which each part of
the body is composed contains many different types of
somatic cell, along with stem cells (embryonic stem cells or
adult somatic stem cells) that can undergo unlimited self-
renewal and differentiate into different somatic cells
during embryonic development. The two broad types of
mammalian stem cell that have been identified so far are
embryonic stem cells, which are isolated from the inner cell
mass of blastocysts, and adult stem cells, which are found
in adult tissues.rker Society. Published by Elsevier Taiwan LLC. All rights reserved.
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certain circumstances, migrate to the injured tissue and
undergo cell division to produce daughter cells that
continue to differentiate into other lineages of cells which
can replace dead cells and repair damaged tissue, thus
maintaining the tissue’s homeostasis.1 The existence of
adult stem cells helps to explain why some tissues have
a strong regenerative capacity. It is well established that
the adult gastrointestinal and blood system are maintained
throughout life by the division and differentiation of stem
cells.2,3 In other adult tissues, notably the liver, quiescent
or “facultative” stem cells are believed to become acti-
vated under conditions of stress and regeneration, but
these do not participate in tissue maintenance in normal
circumstances.4
Despite their potential importance in organ physiology
and regenerative medicine, the existence and role of stem
cells in most adult tissues is still controversial or ill-defined.
Recently, as one advantageous technique for treating
injured tissues and organs than can overcome prior prob-
lems and show a better therapeutic effect, new attention
has been focused on a novel approach using cells capable of
self-renewal and differentiation as a source of trans-
plantation for damaged tissues and organs. Typical exam-
ples of such cells include tissue progenitor cells,
mesenchymal stem cells, and hematopoietic stem cells.
For example, driven by a desire to find sources for new
beta-cells in patients with type 1 diabetes, intense efforts
have been directed towards obtaining evidence for stem
cells (or at least adult cells that can give rise to beta-cells)
in the adult pancreas. A variety of injury models has been
used for this purposedincluding partial pancreatectomy,
pancreatic duct ligation, and treatment with the beta-cell
toxin streptozotocindall showing varying degrees of beta-
cell neogenesis.5e8 As is true in terms of identifying the cell
of origin of pancreatic tumors, controversy exists over the
origin of new beta-cells following injury. Evidence exists for
beta-cell derivation from multiple sources, including pre-
existing beta-cells as well as progenitor cells that reside
within the pancreatic ducts, islets, and bone marrow.9e11
In order to address the question of whether beta-cells
arise by the duplication of existing beta-cells or from non-
beta-cells (whatever the source), Dor et al devised
a “pulse-chase” method for labeling adult beta-cells and
their progeny. These experiments demonstrated that the
percentage of labeled beta-cells did not decrease with
time, even following partial pancreatectomy, indicating
that few if any new beta-cells were derived from an unla-
beled (i.e., progenitor) cell.12 These results do not,
however, rule out the possibility that pancreatic stem cells
do exist. Stem cells might have a potential that is limited to
nonendocrine lineages, or they may become activated only
in certain settings or upon certain forms of injury. Such
settings might be recreated in cancer or with certain
in vitro growth conditions.
Particularly noteworthy is the possibility that pancreatic
cells that express the intermediate filament protein nestin,
a marker of neural stem cells, could represent pancreatic
stem cells.13 Nestin-positive cells isolated from adult islets
can undergo endocrine and exocrine differentiation
in vitro.14,15 Further, a clonal culture of cells that coex-
press nestin and Pdx1, which have the capacity to undergoexocrine, endocrine, and neuronal differentiation, has
been recently reported.16 Although recent reports have
suggested that nestin expression is restricted to non-
epithelial cells in the pancreas,17 it remains possible that
nestin may mark a small population of somatic stem cells in
many adult tissues.
The adult mammalian liver has been shown to have
a high regenerative capacity; in response to chronic liver
diseases, liver injury, or hepatectomy, repopulation occurs
by the proliferation of progenitor cells located in the liver,
known as oval cells, when hepatocyte replication is
impaired or delayed.18 Detailed mechanisms of the stages
leading to liver progenitor cell activation have been studied
using animal models of hepatocarcinogenesis and liver
regeneration after toxic chemical injury. Under these
conditions, small oval cells with a large nuclear-to-
cytoplasm ratio containing an oval-shaped nucleus were
specially expanded to increase the number of cells present.
The histoimmunochemical analysis suggested that epithe-
lial oval cells residing within the canal of Hering could be
resident liver progenitor cells, which are high expressors of
the hematopoietic stem cell markers CD34, c-kit (CD117),
and Thy-1 (CD90). Such cell populations may become
central players in the future treatment of liver diseases
requiring clinically relevant liver regeneration.19,20
To date, the best characterized adult stem cell pop-
ulation considered to possess multipotent capacity is that
of bone marrow mesenchymal stem cells, often referred to
as multipotent stromal cells (MSCs). These are a heteroge-
neous population of fibroblast-like cells that are found in
most adult organs; MSCs, the archetypal multipotent
progenitor cells derived from cultures of developed organs,
are of unknown identity and tissue wide distribution.21 For
more than a decade, advances have been made in isolating
and expanding MSCs from human bone marrow, umbilical
cord blood, and fat.22,23 Multipotent MSCs maintain stem/
progenitor cell activity and can differentiate into lineages
of many mesodermal tissues including bone, myocardio-
cyte, cartilage, skeletal muscle, and neuron, with different
growth conditions produced by combining them with
specific hormones or growth factors.
Fat tissue consists of mature adipocytes, fibroblasts,
vascular smooth muscle cells, endothelial cells, monocytes,
and lymphocytes. Using collagenase digestion followed by
centrifugation, the pellet called referred to as the stromal-
vascular cell fraction (SVF) has come increasingly into focus
in adipose stem cell research, since this compartment
provides a rich source of pluripotent adipose tissue-derived
stem cells (ADSCs).24 There is a confusing inconsistency in
the literature when using terms describing multipotent
precursor cells derived from adipose tissue stroma, such as
processed lipoaspirate cells, adipose tissue-derived stromal
cells, preadipocytes, adipose stroma vascular cell fraction,
and others. The term SVF corresponds to enriched ADSCs
and describes ADSCs obtained immediately after collage-
nase enzyme digestion. The critical point is the require-
ment for a detailed molecular and cellular characterization
of multipotent stem cells within the adipose stroma.
Recently, Rodriguez et al described the isolation and
culture of adipose tissue-derived stem cells with multi-
potent differentiation capacity at the single-cell level.25
These cells can maintain their stem cell characteristics
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of human adipocytes. Meanwhile, subcutaneous adipose
tissue is abundant and easy to obtain, and repeatable
access to subcutaneous adipose tissue provides a clear
advantage over the isolation of MSCs from bone marrow.
Liposuction is a common surgical procedure that is safe,
and a large number of cells can be obtained with minimal
risk.
ADSCs have been reported to have the potential for
endothelial and macrophage differentiation.26 In addition,
an initial effort has been made regarding the differentia-
tion of ADSCs across the germ layer-specific tissues (“cross-
differentiation”) into nonmesenchymal tissues such as
neurons or endocrine pancreatic cells.27 Here, we decided
to use the term ADSCs in our review as a compromise, and
then only for cells that we were able to passage many times
and that showed multipotential differentiation capacity,
and/or could be molecularly characterized using a multi-
panel of mesenchymal differentiation markers (Table 1 and
Fig. 1).
This review will focus on isolation and purification
procedures for ADSCs, their molecular characterization,
and their capacity for differentiation that could be
employed in regenerative medicine. Considering future
prospects, we will also discuss the mechanisms and future
role of ADSCs in tissue engineering and in the repair and
regeneration of injured tissue.
Isolation and characterization of adipose-
derived mesenchymal stem cells
ADSCs are morphologically similar to MSCs obtained from
bone marrow or other tissue after placing it in growthTable 1 Molecular phenotype of adipose tissue-derived
stem cells (ADSCs).
ADSC-positive cellular
markers and genes
ADSC-negative cellular
markers and genes
CD13 CD 31
CD29 CD 34
CD44 CD45
CD49 CD 117
CD90 CD 13 3
CD105 HLA-DR
CD106 STRO-1
CD166 Lin
Fibronectin HLA II
aSMA
Vimentin
Collagen-1
All the gene and surface marker expression profiles apply to
in vitro-expanded cells, not primary cells.
As a minimal prerequisite, mesenchymal stem cells must
express CD105 and CD90 and lake the hematopoietic Ilineage
markers c-kitPCD34PCD45 and H LA-DR (printed in boldface).
aSMAZ smooth muscle cell-specific alpha actin; ADSCZ adi-
pose tissue-derived mesenchymal stem cell; HLAZHuman
leukocyte antigen.medium in vitro. ADSCs possess the progenitor activity to
differentiate into cells of mesenchymal origin, such as
adipocytes, myocytes, chondrocytes, and osteocytes.
Previous studies adjusting the conditions of the culture
media used to grow ADSCs showed that most of the
successful media contained high concentrations of Ca2þ
ions, which may induce or enhance the differentiation of
ADSCs.
Here we followed the protocol established by
Dr. Chang,28 which employs the growth medium K-NAC and
grows human ADSCs in K-NAC medium with a lower calcium
level (0.09 mM), as the low-calcium K-NAC medium may
prevent differentiation and prolong the lifespan of the
ADSCs.28 Another major feature of the K-NAC medium is its
supplementation with the antioxidants NAC and Asc-2P;
NAC is a cysteine prodrug that enhances the production of
glutathionine. The extra supplementation with these two
chemicals may change the cellular redox conditions and
enhance the progenitor potential and lifespan of the stem
or precursor cells. Indeed, culturing the ADSCs in K-NAC
medium gave rise to significantly better proliferation
capacity, and cultures could be maintained for as long as 20
or more passages without losing their mesenchymal stem
cell markers.
Other factors such as donor age, fat tissue type (white or
brown adipose tissue), and localization (subcutaneous or
visceral adipose tissue) of the adipose tissue, type of
surgical procedure, culturing conditions, plating density,
and media formulations are also able to affect the growth
rate and differentiation capacity of ADSCs. However,
neither the type of surgical procedure nor the anatomical
site of the adipose tissue affects the total number of viable
cells that can be obtained from the SVF fraction. Discarded
adipose tissue was collected during surgery with the
informed consent of the patients, and approval by the
hospital. Further, the Institutional Review Board regulates
all research activities involving human subjects.
The protocols below describe in detail how we isolated
the ADSCs in our laboratory (Fig. 2). In brief, immediately
after the biopsy, adipose tissue (0.1e2 mg) was transported
from the hospital to the laboratory in 15 mL ice-cold growth
medium (K-NAC medium with 10% fetal calf serum). In the
laboratory, using a sterile scalpel and forceps, we cut the
biopsy into small pieces and maintained these in a digestion
buffer in a culture dish under a laminar flow hood. Tissue
without fat (white, soft and easy to shred) was discarded
(some biopsies contained a majority of nonadipose tissue).
Small pieces of tissue were then digested with 5 mL
collagenase A solution. Collagenase digestion was per-
formed at 37 C in a water bath. The tube was shaken
vigorously every 5 minutes until dissociation of the tissue
pieces occurred. This took between 20 and 30 minutes
depending on the size of the adipose tissue fragments.
Collagenase digestion was stopped after 30 minutes even if
a few fragments were not totally dissolved. The collage-
nase digestion reaction was stopped by adding 10 mL
DMEMþ 10% fetal calf serum medium.
The crude SVF was separated from the adipocyte frac-
tion by centrifugation at 800 g for 10 minutes at room
temperature. The fat and oil fractions (the upper fraction)
were discarded, and cells from the SVF were seeded onto
one (or two if starting with 2 g of tissue) 100-mm culture
Figure 1 Flow analysis of human adipose-derived stem cells (ADSCs). Cells of the human ADSC stable cell line PLA6 were har-
vested and specific cell surface antigens were detected. Cells stained with a fluorescein isothiocyanate (FITC)-conjugated
nonspecific IgG were examined as a control. Flow cytometric analysis shows that human ADSC-PLA6 cells do not express CD31,
CD34, and CD45, but do express CD29, CD90, and CD44.
Figure 2 Diagram showing the procedure for acquiring adipose tissue and isolating adipose-derived stem cells (ADSCs). In brief,
adipose tissue was collected by needle biopsy or liposuction aspiration. ADSCs were isolated from adipose tissue by washing the fat
tissue several times with 1 phosphate-buffered saline containing 5% penicillin/streptomycin before mincing. After removal of the
debris, the sample was placed in a sterile tissue culture plate with 0.05% collagenase digestion buffer for tissue digestion. The
adipose sample was then pipeted up and down several times to further disintegrate any adipose tissue aggregates. After inacti-
vation of collagenase with K-NAC medium with 10% fetal calf serum (FCS), the supernatant was aspirated, and the cell pellet was
resuspended in a maximum of 5 mL K-NAC medium supplemented with 10% FCS. After centrifugation, the cell suspension was
remixed and filtered through a 100-mm cell strainer. Finally, cell pellets were plated onto a tissue culture plate and incubated at
37 C in 5% carbon dioxide in an incubator.
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Table 2 Experimentally used chemicals and growth
factors that trigger the differentiation of adipose tissue-
derived stem cells (ADSCs).
Type of differentiation Differentiation factors
Adipogenic Insulin, IBMX, dexamethasone,
rosiglitazone, indomethacin,
Chondrogenic 5-Aza BMP-6, 5-Aza BMP-7, GFG-2,
TGF-b1, TGF-b2, TGF-b3,
dexamethasone, IGF-1
Osteogenic 1,25(OH)2D3, b-glycerophosphate,
ascorbic acid, BMP-2,
dexamethasone, valproic acid.
Cardiomyogenic
differentiation
TSA, 5-Aza
Hepatic HGF,OSM,DMSO
Neurogenic EGF, FGF, 25uM fluvastatin, B27/
Neurobasal medium (B27/N
medium), 5-azacytidine
Pancreatic/
endocrine
Activin-A exendin-4,
pentagastrin, HGF, nicotinamide,
high glucose concentration
l,2B(OH)2D3Z 1,25-dihydroxys-cholecalciferol; BMPZ bone
morphogenetic; DMSOZ dimethyl sulfoxide; EGFZ epidermal
growth factor; FGFZ fibroblast growth factor; HGF, hepatocyte
growth factor; IBMXZ 3-isobutyl-1-meyhylxanthine; IGFZ in-
sulin-like growth Factor; ILZ interleukin; OSMZ oncostain M;
TGFZ transforming growth factor; TSAZ trichostatin A: 5-Aza,
5-azacytidine.
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the culture medium was replaced with fresh medium, and
the adherent cells were maintained for expansion.
Adherent cells were dissociated when they reached 60e70%
confluence. ADSCs were shown to be able to proliferate in
culture for more than 10 passages without reaching
senescence.
Subsequently, for the transfer, culture and subculture of
ADSCs, the culture medium was aspirated off, and the cells
were washed with 1 phosphate-buffered saline. The
phosphate-buffered saline was then aspirated off and 1 mL
trypsin solution added, ensuring that the trypsin covered
the cell monolayer. The culture was then incubated at 37 C
in 5% carbon dioxide for 2e3 minutes. After checking under
an inverted microscope that the cells had detached from
the bottom of the dish, 10 mL growth medium was added to
inactivate the trypsin, and the cells were resuspended by
pipeting several times. The cells were then transferred to
a sterile tube and centrifuged at 800 g for 5 minutes at
room temperature. The medium was aspirated off, and the
cell pellet was resuspended in 5 mL growth medium by
pipeting up and down two or three times.
When the cells had been counted, 2.5 105 cells were
added to 10 mL prewarmed growth medium and then
transferred to a 100-mm dish, the medium being changed
every other day. Three to four days later, the cultures were
trypsinized, as for the centrifugation step above. Cultures
were subcultured before the cells had reached 70%
confluence. The cells were harvested, pipeted into freezing
tubes and stored in liquid nitrogen.
The name adipose derived stem cells has been utilized
as these cells display additional and specific characteris-
tics. Human MADS are isolated from human adipose tissue,
and human MADS cell lines can be established using the
protocol above. Cells exhibit characteristics similar to
those of mesenchymal stem cells, i.e., they have the
capacity for self-renewal, as cells can be expanded in vitro
for more than 20 population doublings (i.e., around 30
passages in our hands so far) while maintaining a normal
diploid karyotype and the potential to undergo differenti-
ation into adipocytes, chondrocytes/osteoblasts, hepato-
cyte, islet b-cells, and gial-like cells (Table 2). In in vitro
cultivation, these cells enter the adipose lineage at a high
rate, the differentiation yield being estimated to be more
than 80%, and they differentiate into cells displaying
a unique combination of properties similar to those of
native adipocytes. Therefore, ADSCs are an appropriate
model cell line with which to study human fat cell metab-
olism and to uncover the genes involved in the early steps
of adipogenesis.
According to our characterization, ADSCs must express
CD44, CD90, and CD105 (Table 1 and Fig. 1), and must lack
expression of the endothelial lineage and hematopoietic
lineage markers CD31, CD34, and CD45 (Table 1 and
Fig. 1).29e31 The possible known ADSC expression profile of
surface markers and genes is summarized in Table 1
according to data derived from our analysis and other
published literature, and these expression data prove that
polypotent ADSCs are adult progenitor cells. Meanwhile,
the lack of HLA-DR expression and the immunosuppressive
properties of ADSCs make these cells suitable for in vivo
allogenic transplantation procedures as they are free of therisk of tissue rejection. ADSCs do not provoke in vitro
alloreactivity of incompatible lymphocytes, and they can
suppress mixed lymphocyte reactions and lymphocyte
proliferative responses to mitogens. These findings support
the idea that ADSCs share immunosuppressive properties
with bone marrow MSCs and therefore might represent an
alternative source for stem cell therapy.
Mechanisms of potential therapeutic utility of
ADSCs: Lineage-specific differentiation
potential
Differentiation in osteogenesis
Several studies have focused on the utilization of ADSCs or
MSCs as an alternative to the use of autologous chon-
drocytes to repair damage to the articular cartilage in the
knee.32 Many studies have shown that ADSCs can be
differentiated in culture into osteoblasts and chon-
drocytes.33,34 In our analysis, osteogenesis could be induced
using culture medium supplemented with 1 nM dexameth-
asone, 2 mM b-glycerolphosphate, and 50 mM ascorbate-2-
phosphate. The ADSCs were maintained in this medium
for approximately 2 weeks, and the osteogenic medium was
replaced every 2e3 days. In vitro osteoblast differentiation
was commonly monitored using the marker osteocalcin,
which was sequentially expressed during the differentiation
process. Mineralization was assessed by staining the cells
with 40 mM Alizarin Red (pH 4.1) after fixation in 10%
formalin.
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osteogenic and bone-forming capacities of ADSCs in porous
b-tricalcium phosphate as a scaffold on which to implant
the ADSCs for bone regeneration.35 The availability of a cell
source replacing human bone would be strongly beneficial
for cell therapy, bone tissue engineering, and the devel-
opment of new therapeutic options to enhance the regen-
erative capacity of human bone. Further, the in vivo
formation of bone was investigated in nude mice using b-
tricalcium phosphate scaffolds seeded with ADSCs.36
In addition, Lendeckel et al used adipose-derived stem
cells mixed with autologous fibrin glue to keep the stem
cells in place and to augment the limited amount of
bone available for calvarial reconstruction, with milled
cancellous bone serving as an osteoconductive scaffold.37
Mechanical fixation was achieved by two large, resorbable
macroporous sheets that also acted as a soft tissue bar-
rier. The postoperative course was uneventful, and
computed tomography scans showed new bone formation
and near-complete calvarial continuity 3 months after
transplantation.
Taken together, these two in vivo studies utilizing these
ADSCs are very attractive for cartilage and bone tissue
engineering since subcutaneous fat is abundant in the
human body and the liposuction procedure is minimally
invasive for the patient.
Differentiation into hepatocytes
In recent years, various reports have indicated that the
growth of ADSCs in a medium under specific conditions
encourages their differentiation toward the endoderm
hepatocyte lineage. These cells have acquired the capability
for hepatocyte-specific synthetic functions, albumin
production, low-density lipoprotein uptake, ammonia
detoxification, drug metabolism, and ammonia clearance.
Moreover, transplantation of these cells into different animal
models of liver failure has demonstrated that these cells can
recover liver functionand improve themarkers of liver injury.
First, Kim et al intravenously injected ADSCs into
a mouse model with partial hepatectomy and showed the
integration of ADSCs into the liver,38 which suggested that
mesenchymal stem cells derived from adipose tissues could
be utilized for cell therapy in the liver. Afterward, other
groups used various cytokine mixtures to induce ADSCs to
differentiate into functional hepatocyte-like cells. In 2005,
Seo et al were the first to show that human ADSCs differ-
entiated into hepatocyte-like cells upon treatment with
hepatocyte growth factor, oncostatin M, and dimethyl
sulfoxide.39
Banas et al further sorted CD105þ cells from ADSCs and
treated them with fibroblast growth factor and hepatocyte
growth factor for 3 weeks. During the step of hepatic
differentiation, the cells showed a remarkable transition
from a bipolar fibroblast-like morphology to a round
epithelium-like shape. When treated with dexamethasone
to induce cell maturation, the cells became quite dense
and round with clear or double nuclei after they had
reached the late stage of differentiation.40 The hepato-
genic potentiality of ADSCs was confirmed by the detection
of hepatic-specific markers and biochemical functions.Albumin, the major protein produced by the hepatocytes,
was synthesized and secreted into the medium at days 30
and 50. The expression and activity of the microsome
cytochrome P enzymes involved in drug and xenobiotic
metabolism, as well as sterol and bile acid synthesis, indi-
cates hepatocyte specificity. The authors then implanted
the ADSCs-derived hepatocytes into CCl4-injured nude mice
and observed direct incorporation into the liver. In those
mice, some liver functions, such as ammonia concentration
level, were improved, as was the level of glutamicepyruvic
aminotransferase level in the peripheral blood, which is
a marker of the damaged liver.
Recently, Dr. Yamamoto’s group analyzed the gene
expression profiles of ADSC-derived hepatocytes using
several microarraymethods.41 This report provides evidence
that the transcriptome and signal pathways of ADSC-derived
hepatocytes are similar to those of human primary hepato-
cytes. A decrease in Twist and Snail expression, as well as
upregulated E-cadherin and a-catenin, indicated that
epithelial mesenchymal transition (EMT) occurred in the
differentiation of ADSCs into hepatocytes.
Liang et al found that the mitogen-activated protein
kinase pathway is involved in the hepatogenic induction
process of ADSCs in vitro, and the extracellular signal-
regulated kinase pathway seems to play a more important
role in this step than do the c-Jun N-terminal kinase and
p38 pathways42. Several groups have shown that culturing
ADSCs in a cocktail of growth factors can differentiate them
into cells that take on hepatocyte properties. Analysis of
these cells on both transcriptional and translational levels
has demonstrated the activation and expression of several
hepatocyte-specific pathways after differentiation. The
efficiency of differentiation may not, however, be
adequate for therapeutic application.
More recently, in 2010, the latest study carried out by
Lue et al identified five critical transcriptional factors
important in hepatocyte development that were missing in
these growth factor-driven hepatocyte-like cells, and
speculated that a deficiency of these factors was contrib-
uting to incomplete transdifferentiation. In summary, they
transfected FOXA1, FOXA2, SOX17, GATA4 and HNF4a
factors to ADSCs using lentiviral vectors.43 The data implied
that transducing ADSCs with a combination of endodermal
transcriptional factors could indeed result in an enhance-
ment of albumin gene expression when compared with
untransduced ADSCs after 10 days of culture. Thus, the
direct transdifferentiation of MSCs into endoderm-like cells
rather than growth factor-driven hepatocyte-like cells may
be another potential route for the establishment of
a therapy for the injured liver.
Differentiation to islet beta cells
Adipose tissue is a noteworthy organ that regulates the
body’s fat mass and nutrient homeostasis. It secretes a large
number of adipokines that modulate homeostasis, blood
pressure, and lipid and glucose metabolism. Adipokines such
as leptin, adiponectin, and visfatin are known insulin-
sensitizers and play a major role in glucose homeostasis.
In 2003, Kojima et al showed that extrapancreatic
insulin-producing cells could be detected in multiple
ADSCs and their use in regenerative medicine 59organs, including the liver, spleen, bone marrow, and
adipose tissue of diabetic mice.44 In the same year, Dr. Roy
found adipocytes from a carp that could express the insulin
gene and secrete immunoreactive and biologically active
insulin.45 This evidence directly supports the possibility
that ADSCs can differentiate into insulin-producing cells.
Notably, Timper et al showed that ADSCs cultured in high
glucose (25 mM), hepatocyte growth factor (5 ng/mL), and
several other factors (exendin-4, pentagastrin, activin-A,
betacellulin, and nicotinamide) could differentiate into
insulin-producing cells.46 Initially, these cells expressed not
only the stem cell markers nestin, ABCG2, SCF, and Thy-1,
but also the pancreatic transcription factor Isl-1. After
3 days’ treatment followed by upregulation of Isl-1, pdx-1,
and Ngn-3 expression in mRNA, C-peptide-positive cells
could be found among the differentiated ADSCs. In addi-
tion, these cells also released somatostatin into the culture
medium. Another group, that of Lee et al, used regener-
ating pancreas extract to induce ADSCs for pancreatic
differentiation.47 Pancreas extract from regenerating
pancreas after partial pancreatectomy is known to contain
factors that induce islet neogenesis in rats with
streptozotocin-induced diabetes. All these features make
ADSCs the pre-eminent candidate to differentiate into the
pancreatic endocrine lineage for use in cell-based therapies
for diabetes.
Chandra et al used a similar method of culture with liver
extracts to transform mesodermal ADSCs into definitive
endoderm lineage, then into pancreatic endoderm, and
finally into islet-like cell aggregates.48 Their differentiation
protocol was divided into three stages. First, definitive
endoderm differentiation was achieved with insuline
transferrineselectin, 4 nM activin A, 0.5 mM sodium buty-
rate, and 50 nM 2-mercaptoethanol. Pancreatic endoderm
was induced in the next step with 0.3 mM taurine, and
finally pancreatic hormone-expressing islet-like cell aggre-
gates were induced with GLP-1, niacin, and a supra-
physiological level of taurine (3 mM) for 5 days. In vivo,
transplantation of mature islet-like cell aggregates by
implanted capsules could restore normoglycemia within
2 weeks in streptozotocin-induced diabetic mice.
A further research group used human eyelid adipose-
derived stem cells that could also normalize hyperglycemia
in diabetic mice. For nuclear reprogramming methods,
exogenously induced expression of the Pdx1 gene, a key
regulator of pancreatic bud development and beta-cell
differentiation, induces the differentiation of both embry-
onic stem cells and bone-marrow-derived mesenchymal
stem cells into insulin-producing cells.49 Kajiyama et al
showed that transfer of the Pdx1 gene into ADSCs could
differentiate them into insulin-producing cells in vivo,
significantly decreasing blood glucose levels and increasing
survival rates in mice with streptozotocin-induced dia-
betes.50 These pieces of research may be a useful reference
when considering the clinical application of ADSCs in
developing a cell-based therapy for diabetes mellitus.Neuronal differentiation
The central nervous system, made up of the brain and
spinal cord, is an amazing nerve impulse conductionmachine. Peripheral nerves link the brain and spinal cord to
the other parts of the body, such as muscles and skin. The
nervous system consists of two types of cell: nerve cells
(neurons) and their associated supporting cells, glial
(neuroglial) cells, which occupy the spaces between
neurons and release neuronal growth factors, neuro-
protective molecules, and neuronal transmitters that are
essential for maintaining the survival and function of
neurons.
The nervous system possesses some very fragile struc-
tures that can be damaged by pressure, and key mediators
in the regeneration of such injured nervous tissue are glial
cells.51 The three types of supporting cell in the central
nervous system are the astrocytes, oligodendrocytes, and
microglia. The supporting cells of the peripheral nervous
system are known as Schwann cells. The therapeutic
approach usually uses direct end-to-end surgical repair of
the injured nerves for minor damage, whereas autologous
nerve grafts are required for larger defects. Despite
tremendous surgical advances in recent years, functional
recovery is still poor, and neuronal cell therapy and tissue
engineering techniques enhancing the beneficial endoge-
nous responses to nerve injury could provide a novel ther-
apeutic strategy.
Recent studies have shown that ADSCs can be induced to
differentiate into Schwann-like cells and have compared
this differentiation potential with that of bone marrow
stromal cells (BMSCs);52 we will now primarily discuss the
use of ADSCs for neuronal therapy after brain injury, trau-
matic injuries, and demyelinating lesions. Many recent
reports have indicated that the ADSCs can also be induced
into neurospheres and neuronal-like cells in vitro, and that
an intracerebral transplantation of ADSCs can improve the
neurological deficits seen after cerebral ischemia in mice or
rats.27,53e55 Thus, ADSCs could be an ideal alternative cell
source for neuronally related cells. Several studies have
indicated that ADSCs could be converted into neurospheres,
and that these neurospheres could be induced to become
neuron-like cells. Some of those neuron-like cells can even
form myelin structures around neuronal neurites.
Briefly, ADSC were taken through three to five passages
to grow them detached, and were then replated in serum-
free DMEM/F12 medium supplemented with epidermal
growth factor and basic fibroblast growth factor. Few cells
adhered to the surface of the flasks. A large number of
small spheres of floating cells appeared after 2e4 days in
the conversion culture, and these spheres were able to
proliferate in vitro for up to 2 months. Neurospheres could
be passaged every 7e10 days, with an estimated doubling
time of 3 days. More than 80% of the ADSCs converted into
neurospheres, and about 70% of neurosphere cells were
able to express nestin protein, whereas a small proportion
(less than 10%) of the neurosphere cells expressed b-tubulin
III, the glial marker GFAP, S-100, and p75 in neurosphere
cells. As soon as the neurospheres were plated in poly-L-
lysine-coated slides cultured in B27/Neurobasal medium
(B27/N medium), they began to grow attached, and finally
gained a neuronal morphology that was positive for
neuronal marker b-tubulin III and GFAP.
A recent study has employed a different induction
method. ADSCs were first exposed to 5-azacytidine,
a demethylating agent capable of changing gene expression
60 K.-H. Cheng et al.through demethylation.56 Further differentiation was ach-
ieved by maintaining the cells in Neurobasal medium con-
taining B27 supplement to induce neural differentiation.56
In our studies, we have also been able to demonstrate
the ability of ADSCs to differentiate into neuron-like cells
by simply maintaining ADSCs in K-NAC medium containing
25 mM fluvastatin for 3 days to obtain neuron-like cells that
were positive for two neural markers, GFAP and MAP. The
success and progress of the in vitro studies of ADSCs has no
doubt led us to the fundamental question of whether these
cells are capable of survival and are able to function after
transplantation into the central or peripheral nervous
system.
One recent study has described the survival and
migration ability of ADSCs that had been transplanted into
rats. This group cultured ADSCs in Neurobasal medium with
B27 supplement, 5-azacytidine, and growth factors.57
After implantation into the lateral ventricle of the rat
brain, the ADSCs were able to survive and migrated to
multiple areas of the brain. When ADSCs were transplanted
into animals with focal ischemia resulting from middle
cerebral artery occlusion, they migrated into the injured
cortex, suggesting that ischemia-induced factors facilitate
donor cell migration; in addition, physical behavioral
testing demonstrated that ADSCs improved functional
recovery after cerebral artery occlusion.58 The report
implied that the future clinical application of ADSCs for
tissue engineering would help the development of cell-
based therapeutics for diseases of the nervous system.
Moreover, these ADSCs can secrete many growth factors,
such as pigment epithelium-derived factor, and can
promote survival and neurite outgrowth in neurons.
Neuron-like cells derived from ADSCs may also be useful in
the near future for treating diseases of the peripheral
(e.g., nerve injuries) and central (e.g., multiple sclerosis)
nervous systems.Differentiation to cardiomyocytes
A heart attack (also known as a myocardial infarction)
commonly causes the death of cardiomyocytes, which are
replaced by scar tissue. Cardiomyocytes are terminated,
differentiated cells that cannot regenerate when they are
damaged by cardiac infarction or cardiomyopathy. ADSCs,
on the other hand, are pluripotent cells with the potential
to differentiate into other lineage cells under appropriate
stimulation.
In the first study of 2003, Rangappa et al treated ADSCs
with various concentrations of 5-azacytidine and incubated
them for different lengths of time.59 After treatment with
5-azacytidine, the adult ADSCs were transformed into car-
diomyocytes. Some cells presented binucleation and
extended cytoplasmic processes to adjacent cells after 1
week’s treatment. Further, 20e30% of the cells increased in
size and formed a ball-like appearance after 2 weeks’
treatment. At 3 weeks, some cells began to beat sponta-
neously in culture when observed under a phase-contrast
microscope. These differentiated cardiomyocyte-like cells
stained positive for myosin heavy chain, a-actinin, and
troponin-I in cytochemistry analysis. Moreover, those
differentiated cells maintained this phenotype and had notdedifferentiated up to 2 months after treatment with 5-
azacytidine.
In 2008, Zhang et al applied the same method of culti-
vation of ADSCs in vitro in order to investigate the differ-
ences between ADSCs and MSCs grown in vitro and their
differentiation into cardiomyocytes.60 After treatment with
a consistent dose of 5-azacytidine for several weeks, they
obtained the same cardiomyocyte-like appearance after
3 weeks of treatment. They also claimed that the
percentage of ASCs that differentiated into cardiomyocytes
after treatment with 5-azacytidine was significantly higher
than that of MSCs. This report indicated that ADSCs have
advantages over MSCs in terms of tissue content, homology,
growth, and differentiation rate, suggesting that ADSCs are
a more suitable resource for the differentiation of cellular
cardiomyoplasty than MSCs.
In 2010, Choi et al used 5-azacytidine, a modified car-
diomyogenic medium, and the histone deacetylase inhibitor
trichostatin A in a co-culture of neonatal rat car-
diomyocytes.61 In this study, they examined and monitored
cardiomyogenic differentiation protocols step by step using
5-azacytidine treatment that reduced both cardiac actin
and troponin T mRNA expression. Incubation in modified
cardiomyogenic medium only slightly increased gene
expression (1.5-fold), with 27.2% of cells coexpressing
NKX2.5/sarcomeric a-actin. Most importantly, many of
those differentiated cells showed spontaneous contractions
accompanied by calcium transients in culture. ADSCs
showed Ca2þ transients and contractions synchronous with
surrounding rat cardiomyocytes (at approximately 100
beats/minute). Gap junctions also formed between the
cells, as observed by dye transfer. This method used co-
culture with contracting cardiomyocytes to increase the
differentiation efficiency of ADSCs into cardiomyocytes.62
Together, these observations confirm that ADSCs isolated
from fatty tissue can be chemically transformed into car-
diomyocytes and provide a potential cardiac differentiation
system using autologous cells for myocardial repair or tissue
engineering.Current clinical applications
In the first clinical case, ADSCs were used for the regen-
erative treatment of traumatic calvarial bone defects.37 A
7- year-old girl with post-traumatic calvarial defects was
treated with autologous cancellous iliac bone combined
with ADSCs, fibrin glue, and a biodegradable scaffold.
Postoperative computed tomography scanning showed new
bone formation, and almost complete calvarial continuity
was obtained.
Autologous ADSC therapy was also used to treat fistulas
in patients with Crohn’s disease. In a pilot study of five
patients with Crohn’s disease, the external opening in six
out of eight fistulas could be closed by inoculating the
fistulas with autologous ADSCs.63 Administration of
expanded ADSCs (20e60 million cells) in combination with
fibrin glue is an effective and safe treatment for complex
perianal fistula and appears to achieve higher rates of
healing than fibrin glue alone.64
Since this report was published, ADSCs have also been
used to repair tracheomediastinal fistulas caused by cancer
ADSCs and their use in regenerative medicine 61ablation. In another acute clinical trial, ADSCs were
administered intravenously to patients with acute steroid-
refractory graft-versus-host disease.65 The graft-versus-
host disease resolved completely in five out of six
patients, four of whom were alive, without side effects,
after a median follow-up period of 40 months.
Clinical trials of ADSCs for the treatment of acute
myocardial infarction and chronic heart failure have begun
in Europe. Although the results of these studies have not
been published, ADSCs as well as bone marrow-derived
MSCs are a promising source of cell-based therapies for the
treatment of cardiovascular diseases.Conclusion and future perspective
In our laboratory, we were recently able to isolate and
expand the ADSC culture system from human adipose
tissue. ADSCs share similar characteristics with MSCs, but
the former system has some advantages, including ease of
use, simplicity, and a less invasive process for isolation and
purification.
However, many critical issues regarding the application
of ADSCs for regenerative medicine and tissue engineering
remain unclear. There are several key questions that still
need to be answered, and these must be explored before
clinical trials are conducted: Which factors control the
stem/progenitor activity of ADSCs? How can the processes
of proliferation and differentiation of ADSCs be controlled
in vitro and in vivo? Which signal pathways control these
processes? Will ADSCs cause tumor formation after
transplantation?
Meanwhile, adipose tissues preparation, techniques to
expand and maintain cell culture in vitro, the degree of
purity needed for clinical application, methods for moni-
toring and ensuring the quality of the ADSCs, and tech-
niques to evaluate cell differentiation potential before
implantation should also be identified and standardized.
Although the latest results are very encouraging, more
detailed and confirmatory research is necessary before
future clinical protocols can be constructed. We believe,
however, that ADSCs will be a good autologous resource for
regenerative medicine.References
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